Moody National Bank Trust Division Buys 447 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Moody National Bank Trust Division grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 16,207 shares of the biopharmaceutical company’s stock after acquiring an additional 447 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $1,816,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. FMR LLC increased its position in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after buying an additional 7,157,113 shares during the period. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $1,789,254,000. Finally, Northern Trust Corp grew its holdings in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $111.11 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $138.21 billion, a PE ratio of 300.30, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The business has a 50 day moving average price of $105.45 and a 200-day moving average price of $100.67. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.32) earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Bank of America boosted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,929 shares of company stock worth $5,644,780 over the last quarter. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.